PriceTargets.com logo

COMPASS Pathways - CMPS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.60
  • Forecasted Upside: 746.35%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$3.97 As of 12/20/2024 06:40 PM ET
▲ +0.05 (1.28%)

This chart shows the closing price for CMPS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New COMPASS Pathways Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMPS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMPS

Analyst Price Target is $33.60
▲ +746.35% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $33.60, with a high forecast of $60.00 and a low forecast of $12.00. The average price target represents a 746.35% upside from the last price of $3.97.

This chart shows the closing price for CMPS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in COMPASS Pathways. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/1/2024HC WainwrightLower TargetBuy ➝ Buy$120.00 ➝ $60.00
11/1/2024Maxim GroupLower TargetBuy ➝ Buy$22.00 ➝ $12.00
11/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$23.00 ➝ $18.00
9/10/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$23.00 ➝ $23.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
8/2/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$50.00 ➝ $48.00
7/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
7/23/2024Royal Bank of CanadaInitiated CoverageOutperform$23.00
6/21/2024Cantor FitzgeraldReiterated RatingOverweight
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00
4/30/2024Cantor FitzgeraldReiterated RatingOverweight
4/18/2024Cantor FitzgeraldReiterated RatingOverweight
4/1/2024Morgan StanleyInitiated CoverageOverweight$30.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$120.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$16.00
8/22/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$60.00 ➝ $50.00
8/17/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$21.00
8/4/2023HC WainwrightReiterated RatingBuy$120.00
4/12/2023EF Hutton Acquisition Co. IReiterated RatingBuy$38.00
3/10/2023HC WainwrightReiterated RatingBuy$120.00
3/1/2023CitigroupLower TargetBuy$45.00 ➝ $19.00
2/28/2023EF Hutton Acquisition Co. IReiterated RatingBuy$38.00
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$38.00
12/9/2022OppenheimerLower Target$55.00 ➝ $33.00
11/1/2022Loop CapitalInitiated CoverageBuy$34.00
10/18/2022HC WainwrightReiterated RatingBuy$120.00
10/13/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$78.00 ➝ $50.00
10/13/2022OppenheimerLower Target$65.00 ➝ $55.00
8/5/2022Cantor FitzgeraldLower Target$58.00 ➝ $35.00
8/5/2022CitigroupLower TargetBuy$49.00 ➝ $46.00
2/28/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$80.00 ➝ $78.00
11/22/2021HC WainwrightBoost TargetBuy$100.00 ➝ $120.00
11/9/2021CitigroupBoost TargetBuy$66.00 ➝ $70.00
11/9/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$71.00 ➝ $82.00
11/9/2021Roth CapitalBoost TargetBuy$79.00 ➝ $117.00
10/28/2021OppenheimerInitiated CoverageOutperform$50.00
7/13/2021CitigroupInitiated CoverageBuy$67.00
7/1/2021HC WainwrightBoost TargetPositive$65.00 ➝ $100.00
6/28/2021Berenberg BankReiterated RatingBuy$50.00
6/28/2021Maxim GroupInitiated CoverageBuy$70.00
5/11/2021Cantor FitzgeraldInitiated CoverageOverweight$71.00
4/1/2021Roth CapitalInitiated CoverageBuy$88.00
10/14/2020HC WainwrightInitiated CoverageBuy$65.00
10/13/2020Evercore ISIInitiated CoverageOutperform
10/13/2020CowenInitiated CoverageOutperform
10/13/2020Berenberg BankInitiated CoverageBuy$50.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.24 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 7 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

COMPASS Pathways logo
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $3.97
Low: $3.90
High: $4.20

50 Day Range

MA: $5.03
Low: $3.92
High: $6.44

52 Week Range

Now: $3.97
Low: $3.86
High: $12.75

Volume

1,169,654 shs

Average Volume

638,571 shs

Market Capitalization

$271.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.24

Frequently Asked Questions

What sell-side analysts currently cover shares of COMPASS Pathways?

The following Wall Street research analysts have issued research reports on COMPASS Pathways in the last twelve months: Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, Maxim Group, Morgan Stanley, and Royal Bank of Canada.
View the latest analyst ratings for CMPS.

What is the current price target for COMPASS Pathways?

0 Wall Street analysts have set twelve-month price targets for COMPASS Pathways in the last year. Their average twelve-month price target is $33.60, suggesting a possible upside of 746.3%. HC Wainwright has the highest price target set, predicting CMPS will reach $60.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $12.00 for COMPASS Pathways in the next year.
View the latest price targets for CMPS.

What is the current consensus analyst rating for COMPASS Pathways?

COMPASS Pathways currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMPS will outperform the market and that investors should add to their positions of COMPASS Pathways.
View the latest ratings for CMPS.

What other companies compete with COMPASS Pathways?

Other companies that are similar to COMPASS Pathways include Calliditas Therapeutics AB (publ), ARS Pharmaceuticals, Syndax Pharmaceuticals, ANI Pharmaceuticals and Rocket Pharmaceuticals. Learn More about companies similar to COMPASS Pathways.

How do I contact COMPASS Pathways' investor relations team?

The company's listed phone number is 716-676-6461 and its investor relations email address is [email protected]. The official website for COMPASS Pathways is www.compasspathways.com. Learn More about contacing COMPASS Pathways investor relations.